linjc16/ctgov huggingface dataset:
Sperm Pathology Samples and Morphokinetics

Study Overview
=================
Brief Summary
-----------------
The embryo kinetics may be a new prognostic factor for choosing the embryos with the highest implantation potential. In order to identify the factors that may affect the rate of embryo cleavage, there are many studies about morphokinetics and culture medium, oxygen tension, oocyte quality or type of medication used for ovarian stimulation. However there are no published data with respect to the influence of semen quality in the embryo kinetic. In this study The investigators propose that the sperm quality may has influence in the embryo division.

Official Title
-----------------
Embryo Kinetics and Sperm Quality. Depends on the Sperm Quality the Embryo Cleavage Rate?

Conditions
-----------------
Oligospermia, Cylinical Embryo

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sperm samples with more than 15 mill/ml of sperms, more than 40% of mobile sperms Sperm samples with less than 5 mill/ml of sperms, less than 10% of mobile sperms Exclusion Criteria: sperm samples between 5 to 15 mil/ml of sperms and between 10% to 40% of mobile sperms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Good prognosis<br>Sperm samples >15mill/ml >30% progresive sperms | |
| bad prognosis<br>Sperm samples <5mill/ml <5% progresive sperms | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| embryo division in 2, 3, 4, 5, 6, 7, 8, cells and blastocyst formation | Exact time of cell cleavages | between day 0 and day 5 of development |
Berberine and Cinnamon in Management of Diabetes

Study Overview
=================
Brief Summary
-----------------
In this randomized clinical trial, patients with diabetes will be randomly assigned to receive either Berberine, and Cinnamon supplements or placebo for 12 weeks. Then the glycemic characteristics will be compared in two groups.

Official Title
-----------------
The Effects of Berberine and Cinnamon Supplementation on Diabetes Mangement

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: Berberine+Cinnamon
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20-65 years Diagnosed type-2 diabetes mellitus during the last 1 years Currently only taking oral antidiabetic agents for the last 3 months HbA1c 6.5-8.0% Exclusion Criteria: Patients with an allergy to berberine /cinamon Patients using insulin therapy Patients with raised baseline serum creatinine level (>1.5 mg/dl in men or > 1.2 mg/dl in women) Lactation, pregnancy Patients with any malignancy Patients with unrelated chronic illness Patients with cardiac, liver or respiratory failure

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention<br> | Dietary Supplement: Berberine+Cinnamon<br>* The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract, and trace amounts of vitamins and minerals<br>|
| Placebo Comparator: Placebo<br> | Other: Placebo<br>* Placebo contains Maltodexterin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1C | HbA1C change from baseline | 12th week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting blood sugar | Blood sugar change from baseline | 12th week | 
| blood Insulin | insulin change from baseline | 12th week | 
| Lipid profile | lipid profiles change from baseline | 12th week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Berberine, Cinnamon
Adult Follow-up of Preventive Study With Brief Smoking Intervention for Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to see whether a brief intervention given in adolescence has an effect on smoking in adulthood. The investigators also wanted to clarify the significance of some known psychosocial risk factors of smoking in adulthood.

Conditions
-----------------
Smoking

Intervention / Treatment
-----------------
* Behavioral: Brief intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Born on 1979. Living in Vaasa, Pietarsaari, Kokkola or Seinäjoki at school age. Exclusion Criteria: Other year of birth.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lifestyle counseling<br> | Behavioral: Brief intervention<br>* The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| being a smoker |  | 29 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| state of dental health | Decayed Missing and Filled Teeth (DMFT, DMF), Decayed teeth (DT, D), Community Periodontal Index of Treatment Need (CPITN, CPIN) | 29 years | 
| daily smoking |  | 15 years | 
| amount of cigarettes smoked |  | 29 years | 
| smoking mother |  | 15 years | 
| smoking father |  | 15 years | 
| smoking sister |  | 15 years | 
| smoking brother |  | 15 years | 
| smoking best friend |  | 15 years | 
| smoking best friend |  | 29 years | 
| willingness to experiment with smoking |  | 15 years | 
| self-perceived health |  | 29 years | 
| asthma diagnosis |  | 29 years | 
| recurrent airway tract infections |  | 29 years | 
| self esteem | A 10-step questionnaire | 15 years | 
| smoking time |  | 29 years | 
| received 1-4 brief interventions at school age (Yes/No) |  | 12-15 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoking, Adolescence, Brief intervention
A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Study Overview
=================
Brief Summary
-----------------
This open-label, parallel group study will evaluate the effect of renal function on the pharmacokinetics of RO4995855 following multiple oral dose administration of RO5024048 and assess the effect of renal impairment on safety and tolerability of RO5024048. Adult males or females with either normal renal function or mild or moderate renal impairment will receive RO5024048 orally for 5 days. Target sample size is <50.

Official Title
-----------------
The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: RO5024048


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female adults, 18-75 years of age normal, or mildly or moderately impaired renal function (creatinine clearance >/= 30 mL/min) BMI 18-40 kg/m2 stable renal function agree to abstain from alcohol consumption during study drug adminsitration and limit consumption up to the end of the study agree to abstain from coffein consumption throughout study Exclusion Criteria: positive urine or blood test for drugs of abuse not under a physician's prescription positive for HIV or HCV, or HBV with clinical symptoms or history of hepatitis uncontrolled hypertension renal transplant, dialysis patient, nephritic syndrome clinically significant cardiovascular, central nervous system, gastrointestinal or liver disease or disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Normal Renal Function | Drug: RO5024048<br>* multiple oral doses for 5 days<br>|
| Experimental: 2<br>Mild Renal Impairment | Drug: RO5024048<br>* multiple oral doses for 5 days<br>|
| Experimental: 3<br>Moderate Renal Impairment | Drug: RO5024048<br>* multiple oral doses for 5 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phrmacokinetics of RO49958855 (parent molecule) and metabolites following multiple doses of RO5024048: AUC, Cmax, Tmax T1/2, Ae, Cl |  | sampling days 1 and 3-11 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of renal impairment on safety and tolerability: Adverse events, vital signs, ECG, laboratory parameters |  | Throughout study, ECG and laboratory assessments days 3, 5, 6 and 17 |
The Effect of Osseodensification on Implant Stability in Posterior Maxilla

Study Overview
=================
Brief Summary
-----------------
Implants will be placed in posterior maxilla using two drilling methods; the osseodensification technique and standard drilling protocols. Implant stability will be measured right after implant placement and after 3 months. crestal bone level will be measured after implant placement and after 3 and 9 months.

Official Title
-----------------
Assessment of Dental Implants Stability After Using Osseodensification Method Versus Conventional Drilling in the Posterior Maxilla: A Randomized Clinical Trial

Conditions
-----------------
Implant Stability

Intervention / Treatment
-----------------
* Device: Densah Burs
* Device: Standard drills


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: >18 years; Partially edentulous patients in maxillary posterior area (premolar-molar area) Sufficient ridge height Sufficient ridge width Adequate soft tissue biotype. Patients with adequate inter-arch space for placement of implant prosthetic part. Good oral hygiene Patients who accept to sign an informed consent. Exclusion Criteria: Systemic diseases that contraindicate implant placement, surgical procedures or may impair normal healing Patients with habits that may jeopardize the implant longevity as alcoholism and parafunctional habits. History of radiation therapy to the head and neck Bone augmentation to implant site Heavy smokers (≥ 10 cigarettes per day). Pregnant females Psychiatric problems
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Densah burs<br>Osseodensification using Densah burs | Device: Densah Burs<br>* osseodensification method<br>|
| Active Comparator: Standard drills<br>conventional drilling using standard drills | Device: Standard drills<br>* conventional drilling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant stability | Implant stability will be measured using Osstell (Resonance Frequency Analysis). the measurement unit is Implant stability quotient (ISQ) (range 1-100) | baseline- 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Crestal bone level | Digital radiographs | baseline- 3 months- 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osseodensification, Densah burs
Effect of Acupuncture on Human Brain Activity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use brain imaging technology to examine the way acupuncture affects brain function.

Detailed Description
-----------------
Acupuncture is emerging as an important procedure in complementary medicine. Its mechanism of action remains unclear, but research suggests that its effects are mediated through a widely connected network that is involved in the regulation of mood, behavior, and function of physiological systems. This study will use functional magnetic resonance imaging (fMRI) to monitor the effects of manual acupuncture on the brain function of study participants. Participants in this study will undergo acupuncture one needle at a time. Researchers will then ask participants questions about how they feel and will compare the sensations reported by participants to their images of brain response.

Official Title
-----------------
Modulatory Effect of Acupuncture on Human Brain Activity

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Procedure: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In good physical health
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Acupuncture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Concentration of MitoQ in Human Skeletal Muscle

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine mitoquinone mesylate concentration levels in skeletal muscle samples obtained after intake of an acute oral dose of MitoQ.

Official Title
-----------------
Concentration of Mitoquinone Mesylate in Skeletal Muscle After a Single Oral Dose of MitoQ

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: MitoQ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, Male 18-40 years of age Exclusion Criteria: Previous use of MitoQ or CoQ-10 within 30 days of screening appointment Ongoing use of MitoQ Smoking Ongoing treatment with medications Disease deemed by the MD to infer a risk to participate in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MitoQ<br>Subjects ingest 160 mg of MitoQ | Dietary Supplement: MitoQ<br>* Subjects ingest 8x20 mg MitoQ capsules<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle mitoquinone mesylate concentration | Concentration of mitoquinone mesylate in skeletal muscle | Before oral administration of MitoQ | 
| Muscle mitoquinone mesylate concentration | Concentration of mitoquinone mesylate in skeletal muscle | 1 hours after oral administration of MitoQ | 
| Muscle mitoquinone mesylate concentration | Concentration of mitoquinone mesylate in skeletal muscle | 3 hours after oral administration of MitoQ | 
| Muscle mitoquinone mesylate concentration | Concentration of mitoquinone mesylate in skeletal muscle | 5 hours after oral administration of MitoQ | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood mitoquinone mesylate concentration | Concentration of mitoquinone mesylate in venous blood | Before as well as 0.5, 1, 1.5, 2, 3, 4 and 5 hours after oral administration of MitoQ | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mitochondria-targeted antioxidant, Skeletal muscle biopsies
Serum METRNL Concentration in Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The investigators measured serum METRNL levels in newly diagnosed patients with type 2 diabetes (T2DM) compared with normal glucose tolerance or prediabetes and explored the correlations between its serum levels and various metabolic parameters

Official Title
-----------------
Comparison of Serum METRNL Concentration Between Type 2 Diabetes and Normal Glucose Tolerance

Conditions
-----------------
Diabetes Mellitus, Type 2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have not been diagnosed diabetes mellitus Exclusion Criteria: Person with diabetes who were treated with oral hypoglycemic agent or insulin Individuals with type 1 diabetes, gestational diabetes, active hepatitis/liver cirrhosis, chronic renal failure on hemodialysis, congestive heart failure, or other known major disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes Mellitus<br> | |
| Prediabetes<br> | |
| Normal glucose tolerance<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum METRNL concentration |  | on the 1 day of oral glucose tolerance test |
Preventing Antibiotic-Associated DiarRhea Using Erceflora

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of the pre-biotic Bacillus clausii in preventing antibiotic associated diarrhea among hospitalized immunocompetent Filipino children.

Official Title
-----------------
Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety

Conditions
-----------------
Diarrhea, Infantile

Intervention / Treatment
-----------------
* Drug: Bacillus Clausii Multi ATB Resist
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically stable children with mild to moderate illness admitted for treatment of bacterial infection. Exclusion Criteria: Children with unstable medical condition In any form of immunocompromized state With contraindication to take medication Has taken antibiotics for 3 weeks before start of trial. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Bacillus Clausii Multi ATB Resist | Drug: Bacillus Clausii Multi ATB Resist<br>* Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water<br>|
| Placebo Comparator: 2<br>Placebo | Drug: Placebo<br>* Matched placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in the incidence of antibiotic-associated diarrhea (relative risk) |  | From baseline to end of treatment | 
| All adverse event regardless of seriousness or relationship to the study drug |  | From baseline to end of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in the number of antibiotic-associated diarrhea events per day |  | From baseline to end of treatment | 
| Reduction in the severity of diarrhea events |  | From baseline to end of treatment | 
| Reduction in Gastrointestinal-related symptoms (nausea, vomiting, abdominal pain)over-all reduction in the number of hospitalization days beween control and treatment groups. |  | From baseline to end of treatment | 
| Reduction in C. dificille -associated diarrhea. |  | From baseline to end of treatment |